Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Concetta Crivera

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Journal of the American Heart Association|October 30, 2016
Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis AdmissionsJay M Margolis, Steven Deitelzweig, Jeffrey Kline, et al.
Clinical Therapeutics|October 19, 2016
Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With WarfarinJay M Margolis, Steven Deitelzweig, Jeffrey Kline, et al.
Clinical Therapeutics|June 28, 2017
Overall Effectiveness of Rivaroxaban in Patients with Pulmonary EmbolismLi Wang, Onur Baser, Phil Wells, et al.
Plos One|October 11, 2017
Benefit of early discharge among patients with low-risk pulmonary embolismLi Wang, Onur Baser, Phil Wells, et al.
Journal of Thrombosis and Thrombolysis|February 8, 2019
The value of sPESI for risk stratification in patients with pulmonary embolismPhil Wells, W Frank Peacock, Gregory J Fermann, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolismJeffrey S Berger, Roger Seheult, François Laliberté, et al.
Journal of Health Economics and Outcomes Research|July 21, 2020
Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of CareW Frank Peacock, Craig I Coleman, Phil Wells, et al.
Clinical Therapeutics|October 30, 2016
Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial FibrillationColleen A McHorney, Eric D Peterson, François Laliberté, et al.
Current Medical Research and Opinion|March 25, 2016
Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trialsElaine Nguyen, C Michael White, Manesh R Patel, et al.
Journal of Health Economics and Outcomes Research|July 21, 2020
Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary EmbolismLi Wang, Onur Baser, Phil Wells, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Journal of the American Heart Association|October 30, 2016
Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis AdmissionsJay M Margolis, Steven Deitelzweig, Jeffrey Kline, et al.
Clinical Therapeutics|October 19, 2016
Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With WarfarinJay M Margolis, Steven Deitelzweig, Jeffrey Kline, et al.
Clinical Therapeutics|June 28, 2017
Overall Effectiveness of Rivaroxaban in Patients with Pulmonary EmbolismLi Wang, Onur Baser, Phil Wells, et al.
Plos One|October 11, 2017
Benefit of early discharge among patients with low-risk pulmonary embolismLi Wang, Onur Baser, Phil Wells, et al.
Journal of Thrombosis and Thrombolysis|February 8, 2019
The value of sPESI for risk stratification in patients with pulmonary embolismPhil Wells, W Frank Peacock, Gregory J Fermann, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolismJeffrey S Berger, Roger Seheult, François Laliberté, et al.
Journal of Health Economics and Outcomes Research|July 21, 2020
Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of CareW Frank Peacock, Craig I Coleman, Phil Wells, et al.
Clinical Therapeutics|October 30, 2016
Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial FibrillationColleen A McHorney, Eric D Peterson, François Laliberté, et al.
Current Medical Research and Opinion|March 25, 2016
Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trialsElaine Nguyen, C Michael White, Manesh R Patel, et al.
Journal of Health Economics and Outcomes Research|July 21, 2020
Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary EmbolismLi Wang, Onur Baser, Phil Wells, et al.
Pageof 8